Last week’s hot topic on BPH was NxThera Publishes Rezum II Clinical Study Results on BPH Symptoms written by Margarida Azevedo.
This article is focused on NxThera, Inc., a therapeutic device company responsible for the development of the Convective Water Vapor Energy (WAVE) technology platform for the treatment of benign prostatic hyperplasia (BPH), that published the results from its Rezūm II study. The data from the first year of this multicenter study, revealing the results of transurethral prostate convective water vapor thermal energy treatment of lower urinary tract symptoms (LUTS) secondary to BPH, was published online in The Journal of Urology.
These impressive results led NxThera to recently launch, in the U.S, a limited release of Rezūm System with more than thirty-five patients receiving Rezūm treatment from urologists at five leading U.S. urology clinics in the first 8 days after its release.